Patents by Inventor Richard L. Norton
Richard L. Norton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8921387Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: GrantFiled: June 6, 2011Date of Patent: December 30, 2014Assignee: RB Pharmaceuticals LimitedInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Patent number: 8877225Abstract: The present invention provides a constant release copolymer composition adapted for use in a controlled release formulation for a bioactive agent, such as a formulation adapted for implantation within a patient's body tissues as a depot to release the agent over a period of time, wherein the copolymer provides a substantially constant rate of release of the bioactive agent over the time period for which the depot persists in the body tissues. The copolymer includes a PLG copolymer and a PLG oligomer of about 5-10 kDa average molecular weight, which can lack free carboxylic acid groups. When the PLG copolymer is a low burst copolymer, the constant release copolymer composition is a low burst, constant release copolymer composition adapted for implantation in the body tissues of a mammal, wherein a substantially constant rate of release of the bioactive agent is achieved.Type: GrantFiled: June 3, 2009Date of Patent: November 4, 2014Assignee: Tolmar Therapeutics, Inc.Inventors: Richard L. Norton, Eric Dadey
-
Publication number: 20130210853Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.Type: ApplicationFiled: June 6, 2011Publication date: August 15, 2013Applicant: RB PHARMACEUTICALS LIMITEDInventors: Richard L. Norton, Andrew Watkins, Mingxing Zhou
-
Publication number: 20130202658Abstract: This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof.Type: ApplicationFiled: June 6, 2011Publication date: August 8, 2013Applicant: RB PHARMACEUTICALS LIMITEDInventors: Richard L. Norton, Mingxing Zhou
-
Patent number: 8324343Abstract: The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for carrying out stepwise purification of the biodegradable polyester at multiple pressures or multiple temperatures, or both, are also provided. When the polyester is PLG, a purified PLG copolymer is obtained having a narrowed molecular weight distribution with respect to the unpurified polyester. The purified PLG copolymer can have a polydispersity index of less than about 1.7, less than about 2% monomers, and less than about 10% oligomers. The purified PLG copolymer can exhibit a reduced initial burst effect when incorporated into a controlled release formulation such as a flowable implant adapted to be injected into body tissues.Type: GrantFiled: October 13, 2011Date of Patent: December 4, 2012Assignee: Tolmar Therapeutics, Inc.Inventors: Lester Moore, Richard L. Norton
-
Publication number: 20120108511Abstract: The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for carrying out stepwise purification of the biodegradable polyester at multiple pressures or multiple temperatures, or both, are also provided. When the polyester is PLG, a purified PLG copolymer is obtained having a narrowed molecular weight distribution with respect to the unpurified polyester. The purified PLG copolymer can have a polydispersity index of less than about 1.7, less than about 2% monomers, and less than about 10% oligomers. The purified PLG copolymer can exhibit a reduced initial burst effect when incorporated into a controlled release formulation such as a flowable implant adapted to be injected into body tissues.Type: ApplicationFiled: October 13, 2011Publication date: May 3, 2012Applicant: QLT USA, INC.Inventors: Lester Moore, Richard L. Norton
-
Patent number: 8076448Abstract: The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for carrying out stepwise purification of the biodegradable polyester at multiple pressures or multiple temperatures, or both, are also provided. When the polyester is PLG, a purified PLG copolymer is obtained having a narrowed molecular weight distribution with respect to the unpurified polyester. The purified PLG copolymer can have a polydispersity index of less than about 1.7, less than about 2% monomers, and less than about 10% oligomers. The purified PLG copolymer can exhibit a reduced initial burst effect when incorporated into a controlled release formulation such as a flowable implant adapted to be injected into body tissues.Type: GrantFiled: April 9, 2009Date of Patent: December 13, 2011Assignee: Tolmar Therapeutics, Inc.Inventors: Lester Moore, Richard L. Norton
-
Publication number: 20110245172Abstract: The present invention relates to biocompatible oligomer-polymer compositions for the in situ formation of implants, wherein the implants release a bioactive agent, a metabolite, or a prodrug thereof, at a controlled rate. The sustained release delivery system includes a flowable composition containing a bioactive agent, a metabolite, or a prodrug thereof, and an implant containing a bioactive agent, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become the solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, a biocompatible end-capped oligomeric liquid, and a bioactive agent, a metabolite, or a prodrug thereof.Type: ApplicationFiled: June 3, 2009Publication date: October 6, 2011Applicant: Tolmar Therapeutics, Inc.Inventor: Richard L. Norton
-
Publication number: 20100292195Abstract: A PLG copolymer material, termed a PLG(p) copolymer material, adapted for use in a controlled release formulation for a bioactive material is provided, wherein the formulation exhibits a reduced “initial burst” effect when introduced into the tissue of a patient in need thereof. A method of preparation of the PLG copolymer material is also provided, as are methods of use.Type: ApplicationFiled: February 13, 2008Publication date: November 18, 2010Applicant: QLT USA, INC.Inventors: Eric Dadey, John Middleton, Richard L. Norton
-
Publication number: 20090325879Abstract: The present invention provides a constant release copolymer composition adapted for use in a controlled release formulation for a bioactive agent, such as a formulation adapted for implantation within a patient's body tissues as a depot to release the agent over a period of time, wherein the copolymer provides a substantially constant rate of release of the bioactive agent over the time period for which the depot persists in the body tissues. The copolymer includes a PLG copolymer and a PLG oligomer of about 5-10 kDa average molecular weight, which can lack free carboxylic acid groups. When the PLG copolymer is a low burst copolymer, the constant release copolymer composition is a low burst, constant release copolymer composition adapted for implantation in the body tissues of a mammal, wherein a substantially constant rate of release of the bioactive agent is achieved.Type: ApplicationFiled: June 3, 2009Publication date: December 31, 2009Applicant: QLT USA, INC.Inventors: Richard L. Norton, Eric Dadey
-
Publication number: 20090305957Abstract: The invention provides methods of extracting a biodegradable polyester with a supercritical fluid effective to obtain a purified biodegradable polyester, such as a purified biodegradable poly(lactide-glycolide) (PLG). The supercritical fluid can be carbon dioxide at an elevated pressure, or can be carbon dioxide with one or more cosolvents. Methods for carrying out stepwise purification of the biodegradable polyester at multiple pressures or multiple temperatures, or both, are also provided. When the polyester is PLG, a purified PLG copolymer is obtained having a narrowed molecular weight distribution with respect to the unpurified polyester. The purified PLG copolymer can have a polydispersity index of less than about 1.7, less than about 2% monomers, and less than about 10% oligomers. The purified PLG copolymer can exhibit a reduced initial burst effect when incorporated into a controlled release formulation such as a flowable implant adapted to be injected into body tissues.Type: ApplicationFiled: April 9, 2009Publication date: December 10, 2009Applicant: QLT USA, INC.Inventors: Lester Moore, Richard L. Norton
-
Patent number: 6626870Abstract: A syringe assembly is provided which includes a hollow barrel that has an interior wall. The interior wall defines a chamber that retains medication. The hollow barrel also includes a distal end and a proximal end. The distal end of the hollow barrel has a passageway that is in contact with the chamber. The proximal end of the hollow barrel has an aperture. The syringe assembly also includes a primary plunger tip that is slidably positioned, in fluid tight engagement, with the interior wall. The primary plunger tip has a receptor to engage an engager of an elongated tip plunger rod. The syringe assembly also includes a secondary plunger tip that is slidably positioned, in fluid tight engagement, with the interior wall. The secondary plunger tip also has a receptor to engage an engager of a tip plunger rod. The secondary plunger tip is disposed between the primary plunger tip and the proximal end of the hollow barrel.Type: GrantFiled: March 27, 2000Date of Patent: September 30, 2003Assignee: Artix Laboratories, Inc.Inventors: Cody L Yarborough, Michael R. Duncan, Richard L. Norton, Rajan Bawa, Dominic G. Madril, Christopher J. Barrett
-
Patent number: 6579916Abstract: Disclosed are methods for sterilizing cyanoacrylate prepolymer compositions under visible light irradiation conditions wherein the prepolymer remains in polymerizable form after sterilization.Type: GrantFiled: November 21, 2001Date of Patent: June 17, 2003Assignee: MedLogic Global CorporationInventors: Ian N. Askill, Shane C. Karnik, Richard L. Norton
-
Patent number: 6395293Abstract: The invention is directed to a biodegradable implant precursor having a two-part structure made of an outer sac and a liquid content. The implant precursor is composed of a biodegradable, water-coagulable thermoplastic polymer and a water-miscible organic solvent. When administered to an implant site in an animal, the implant precursor will solidify in situ to a solid, microporous matrix by dissipation of the organic solvent to surrounding tissue fluids and coagulation of the polymer. The invention also includes methods of making the implant precursor, an apparatus for forming the precursor, and a kit containing the apparatus. Also provided are methods of using the implant precursor for treating a tissue defect in an animal, for example, for enhancing cell growth and tissue regeneration, wound and organ repair, nerve regeneration, soft and hard tissue regeneration, and the like, for delivery of biologically-active substances to tissue or organs, and other like therapies.Type: GrantFiled: March 8, 2000Date of Patent: May 28, 2002Assignee: Atrix LaboratoriesInventors: Alan M. Polson, Deryl D. Swanbom, Richard L. Dunn, Charles P. Cox, Richard L. Norton, Bryan K. Lowe, Kenneth S. Peterson
-
Publication number: 20020001608Abstract: The invention is directed to a biodegradable implant precursor having a two-part structure made of an outer sac and a liquid content. The implant precursor is composed of a biodegradable, water-coagulable thermoplastic polymer and a water-miscible organic solvent. When administered to an implant site in an animal, the implant precursor will solidify in situ to a solid, microporous matrix by dissipation of the organic solvent to surrounding tissue fluids and coagulation of the polymer. The invention also includes methods of making the implant precursor, an apparatus for forming the precursor, and a kit containing the apparatus. Also provided are methods of using the implant precursor for treating a tissue defect in an animal, for example, for enhancing cell growth and tissue regeneration, wound and organ repair, nerve regeneration, soft and hard tissue regeneration, and the like, for delivery of biologically-active substances to tissue or organs, and other like therapies.Type: ApplicationFiled: March 8, 2000Publication date: January 3, 2002Inventors: Alan M. Polson, Deryl D. Swanbom, Richard L. Dunn, Charles P. Cox, Richard L. Norton, Bryan K. Lowe, Kenneth S. Peterson
-
Patent number: 6071530Abstract: The invention is directed to a biodegradable implant precursor having a two-part structure made of an outer sac and a liquid content. The implant precursor is composed of a biodegradable, water-coagulable thermoplastic polymer and a water-miscible organic solvent. When administered to an implant site in an animal, the implant precursor will solidify in situ to a solid, microporous matrix by dissipation of the organic solvent to surrounding tissue fluids and coagulation of the polymer. The invention also includes methods of making the implant precursor, an apparatus for forming the precursor, and a kit containing the apparatus. Also provided are methods of using the implant precursor for treating a tissue defect in an animal, for example, for enhancing cell growth and tissue regeneration, wound and organ repair, nerve regeneration, soft and hard tissue regeneration, and the like, for delivery of biologically-active substances to tissue or organs, and other like therapies.Type: GrantFiled: June 26, 1997Date of Patent: June 6, 2000Assignee: Atrix Laboratories, Inc.Inventors: Alan M. Polson, Deryl D. Swanbom, Richard L. Dunn, Charles P. Cox, Richard L. Norton, Bryan K. Lowe, Kenneth S. Peterson
-
Patent number: 5681873Abstract: The invention provides moldable, biodegradable composition for use with bone and other tissues. The composition comprises a poly(caprolactone) thermoplastic polymer processed alone or compounded with a biocompatible, biodegradable substance that controls crystallization of the polymer and functions to soften the composition. The composition may further include a biologically-active agent such as an antibiotic for sustained delivery in an animal, a coloring agent for tinting the composition, and other additives as desired.Type: GrantFiled: October 14, 1993Date of Patent: October 28, 1997Assignee: Atrix Laboratories, Inc.Inventors: Richard L. Norton, Stephen Michael Gregory Knight, Arthur J. Tipton
-
Patent number: 5660849Abstract: The invention is directed to a biodegradable implant precursor having a two-part structure made of an outer sac and a liquid content. The implant precursor is composed of a biodegradable, water-coagulable thermoplastic polymer and a water-miscible organic solvent. When administered to an implant site in an animal, the implant precursor will solidify in situ to a solid, microporous matrix by dissipation of the organic solvent to surrounding tissue fluids and coagulation of the polymer. The invention also includes methods of making the implant precursor, an apparatus for forming the precursor, and a kit containing the apparatus. Also provided are methods of using the implant precursor for treating a tissue defect in an animal, for example, for enhancing cell growth and tissue regeneration, wound and organ repair, nerve regeneration, soft and hard tissue regeneration, and the like, for delivery of biologically-active substances to tissue or organs, and other like therapies.Type: GrantFiled: August 23, 1994Date of Patent: August 26, 1997Assignee: Atrix Laboratories, Inc.Inventors: Alan M. Polson, Deryl D. Swanbom, Richard L. Dunn, Charles P. Cox, Richard L. Norton, Bryan K. Lowe, Kenneth S. Peterson
-
Patent number: 5488713Abstract: Methodology for simulating programs on a single processor host workstation to accurately predict their performance on a target system including multiple processors, including timing interdependent processes and arranging and paralleling the measured times.Type: GrantFiled: July 28, 1993Date of Patent: January 30, 1996Assignee: Digital Equipment CorporationInventors: Richard L. Norton, Karen J. Norton
-
Patent number: 5487897Abstract: The invention is directed to a biodegradable implant precursor having a two-part structure made of an outer sac and a liquid content. The implant precursor is composed of a biodegradable, water-coagulable thermoplastic polymer and a water-miscible organic solvent. When administered to an implant site in an animal, the implant precursor will solidify in situ to a solid, microporous matrix by dissipation of the organic solvent to surrounding tissue fluids and coagulation of the polymer. The invention also includes methods of making the implant precursor, an apparatus for forming the precursor, and a kit containing the apparatus. Also provided are methods of using the implant precursor for treating a tissue defect in an animal, for example, for enhancing cell growth and tissue regeneration, wound and organ repair, nerve regeneration, soft and hard tissue regeneration, and the like, for delivery of biologically-active substances to tissue or organs, and other like therapies.Type: GrantFiled: September 28, 1993Date of Patent: January 30, 1996Assignee: Atrix Laboratories, Inc.Inventors: Alan M. Polson, Deryl D. Swanbom, Richard L. Dunn, Charles P. Cox, Richard L. Norton, Bryan K. Lowe, Kenneth S. Peterson